VERTEX PHARMACEUTICALS INC / MA
(VRTX)CIK 875320 · SEC filings only
harness minimum not met
Not enough resolved promises to grade
1 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.
Resolved promises
Full say-do history
Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.
See Pro →Credibility timeline
Timeline as a list
- May 6, 2025PARTIALOn February 1, Vertex’s Board of Directors approved a new share repurchase program, authorizing the repurchase of up to $3.0 billion of our common stock.
grade
Resolved promises
Full say-do history
Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.
See Pro →Open promises (1) · 18 superseded
Raising full-year revenue guidance to $13.1 billion to $13.2 billion
Vertex’s total revenue guidance of $12.95 billion to $13.1 billion
Company provides full year 2024 product revenue guidance of $10.55 to $10.75 billion
revenue guidance of $11.85 to $12 billion
Company reiterates full year 2022 product revenue guidance of $8.4 to $8.6 billion
product revenue guidance of $9.55 to $9.7 billion
Product revenues $6.7 to 6.9 billion
Product revenues $7.2 to 7.4 billion
Total revenue $11.85 to $12.0 billion
now expects 2020 CF revenues of $5.7 to $5.9 billion
product revenue guidance of $10.55 to $10.75 billion
Vertex’s total revenue guidance of $12.95 billion to $13.1 billion
Product revenues Unchanged $6.7 to 6.9 billion
Vertex is raising its full year 2022 product revenue guidance to $8.6 to $8.8 billion.
Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion
Vertex’s combined Non-GAAP R&D, Acquired IPR&D and SG&A expense guidance includes expectations for continued investment in our multiple mid- and late-stage clinical development programs, commercial and manufacturing capabilities, and approximately $300 million of upfront and milestone payments from existing collaborations and our anticipated transaction with Entrada Therapeutics. Vertex’s guidance is summarized below: FY 2023 CF product revenues $9.55 to $9.7 billion
Vertex today raised its full year product revenue guidance from $10.55-$10.75 billion to $10.65-$10.85 billion.
Company raises full year 2023 product revenue guidance to $9.7 to $9.8 billion
Product revenues $8.4 to $8.6 billion
Credibility timeline
Timeline as a list
- Feb 13, 2019BEATCompany increases full-year 2018 total CF product revenue guidance to $2.9 to $3.0 billion
- Feb 11, 2021BEATnow expects 2020 product revenues of $6.0 to $6.2 billion
- Feb 9, 2022BEATProduct revenues $7.4 to 7.5 billion
- Feb 10, 2023BEATProduct revenues $8.8 to $8.9 billion
- Feb 15, 2024KEPTVertex today raised its full year 2023 CF product revenue guidance to approximately $9.85 billion.
- Feb 13, 2025BEATRaising full-year product revenue guidance to $10.8 billion to $10.9 billion
- Feb 13, 2026BEATtotal revenue guidance now $11.9 to $12.0 billion